SecBot SecBot
PRESS-RELEASE ·Filed Apr 17, 2026

IMTX

https://immatics.com/
BULLISH
Impact 7/10
Horizonweeks Processed7mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight ▲ Bullish

Traders should monitor the AACR presentation for additional clinical details and watch for updates on Immatics' planned pediatric development program, which could expand the addressable market for its PRAME-directed therapies and support future trial designs or partnerships.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$11.17
T+0 close · Apr 17, 2026 · via day close
Latest settled
−16.29%
T+60 · $9.35
Vs SPY
−22.44%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 17 $11.17entry
  2. T+1 · 7mo ago +0.72%α +0.91% · $11.25
  3. T+5 · 7mo ago +1.61%α +1.06% · $11.35
  4. T+20 · 6mo ago 0.00%α −5.37% · $11.17
  5. T+60 · 4mo ago −16.29%α −22.44% · $9.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Immatics announced a deep and ongoing remission in a 17-year-old pediatric patient with advanced nephroblastoma after treatment with its PRAME-directed TCR T-cell therapy (IMA203CD8) under a named-patient use program. The case, to be presented at AACR 2026, demonstrates strong anti-tumor activity across multiple metastatic sites and supports the potential of PRAME-targeted cell therapy in pediatric solid tumors.

Key Facts

  • 17-year-old pediatric patient with PRAME-positive nephroblastoma achieved deep remission after treatment with Immatics' IMA203CD8 TCR T-cell therapy.
  • Remission included marked regression of liver, lung, and brain metastases, ongoing at 6 months post-infusion.
  • Molecular remission confirmed via liquid biopsy with no detectable tumor-derived DNA.
  • Safety events included manageable cytokine release syndrome resolved with standard therapy.
  • Data to be presented in a late-breaking poster at AACR Annual Meeting 2026.
  • Immatics plans a potential Phase 1/2 basket study in pediatric patients with PRAME-positive solid tumors.

Financial Impact

No direct financial impact disclosed, but significant strategic and clinical validation for Immatics' PRAME platform.

pipeline valueclinical validationinvestor sentiment

Risk Factors

  • Single-patient case study with no control group; results may not be reproducible.
  • Named-patient use is not a controlled clinical trial; regulatory path remains uncertain.
  • Forward-looking statements about future trials and commercial potential are subject to development risks.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3276451

Track record

23 reports on IMTX

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+5. Best: +22.12% at T+20 after the May 12, 2026 report. 8 of 13 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $6.24 Now $6.17 −1.12% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $6.55 Now $6.17 −5.73% settles Nov 23
  3. Nov 10, 20266d ago 6-K Neutral 5/10 No price data
  4. Nov 10, 20266d ago Press Release Neutral 4/10 Entry $6.42 Now $6.17 −3.89% settles Nov 17
  5. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  6. Oct 24, 202624d ago Press Release Bullish 6/10 Entry $7.15 to $7.20 Now $6.17 −13.71% ▲ +0.70% +1.96% vs SPY
  7. Oct 23, 202624d ago 6-K Bullish 7/10 Entry $7.31 to $7.20 Now $6.17 −15.60% ▼ −1.50% −0.95% vs SPY
  8. Aug 27, 202611w ago Insider Buy Bullish 6/10 Entry $9.45 to $9.56 Now $6.17 −34.71% ▲ +1.16% +1.05% vs SPY
  9. Aug 26, 202611w ago 6-K Bearish 6/10 Entry $9.36 to $9.46 Now $6.17 +34.08% ▼ −1.07% −0.80% vs SPY
  10. Aug 18, 202612w ago 6-K Neutral 6/10 Entry $9.09 to $9.24 Now $6.17 −32.12% ▲ +1.65% +1.85% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 17, 2026